Publications by authors named "Maria G Cabras"

Claim this Profile
I
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Anastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, Pierre Feugier, Monica Tani, Maria Giuseppina Cabras

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.
Annarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, Anastasios Stathis, Barbara Botto, Maria Giuseppina Cabras

Blood Adv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.
Gian Maria Zaccaria, Simone Ferrero, Eva Hoster, Roberto Passera, Andrea Evangelista, Maria Giuseppina Cabras

Cancers (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL).
Guido Gini, Alice Di Rocco, Luca Nassi, Annalisa Arcari, Maria Chiara Tisi, Maria Giuseppina Cabras

Front Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Olga Mulas, Giovanni Caocci, Daniela Dessì, Daniela Mantovani, Giulia Moi, Maria Giuseppina Cabras

Acta Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Andrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, Maria Giuseppina Cabras, Jeffery Smith

Lancet Haematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study.
Luigi Barberini, Antonio Noto, Claudia Fattuoni, Giannina Satta, Mariagrazia Zucca, Maria Giuseppina Cabras

Molecules· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.
Maria R Ambrosio, Stefano Lazzi, Giuseppe Lo Bello, Raffaella Santi, Leonardo Del Porro, Maria G Cabras

Haematologica· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Emilio Iannitto, Monica Bellei, Sandy Amorim, Andrés J M Ferreri, Luigi Marcheselli, Maria Giuseppina Cabras

Br J Haematol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of the aryl hydrocarbon receptor and risk of lymphoma subtypes.
Sonia Sanna, Giannina Satta, Marina Padoan, Sara Piro, Angela Gambelunghe, Maria Giuseppina Cabras

Int J Mol Epidemiol Genet· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.
Luca Ceriani, Maurizio Martelli, Annarita Conconi, Pier L Zinzani, Andrés J M Ferreri, Maria G Cabras

Br J Haematol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Annalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, Ercole Brusamolino, Andrea Evangelista, Maria Giuseppina Cabras

Lancet Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.
Pier Luigi Zinzani, Cinzia Pellegrini, Annalisa Chiappella, Alice Di Rocco, Flavia Salvi, Maria Giuseppina Cabras

Blood· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).
Roberto Mario Santi, Manuela Ceccarelli, Elisa Bernocco, Chiara Monagheddu, Andrea Evangelista, Maria Giuseppina Cabras

Thromb Haemost· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.
Marco Lucioni, Emilio Berti, Luca Arcaini, Giorgio A Croci, Aldo Maffi, Maria Giuseppina Cabras

Cancer Med· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
Annalisa Arcari, Annalisa Chiappella, Michele Spina, Luca Zanlari, Patrizia Bernuzzi, Maria Giuseppina Cabras

Leuk Lymphoma· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders.
Maria Giuseppina Cabras, Emanuele Angelucci

Expert Opin Pharmacother· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).
Stephane Chauvie, Fabrizio Bergesio, Federica Fioroni, Marco Brambilla, Alberto Biggi, Maria G Cabras

Phys Med· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.
Andrés J M Ferreri, Giovanni Donadoni, Maria Giuseppina Cabras, Caterina Patti, Michael Mian

J Clin Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.
Luca Ceriani, Maurizio Martelli, Pier Luigi Zinzani, Andrés J M Ferreri, Barbara Botto, Maria Giuseppina Cabras

Blood· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).
Alessandra Tucci, Maurizio Martelli, Luigi Rigacci, Paola Riccomagno, Maria Giuseppina Cabras

Leuk Lymphoma· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.
Giuseppe Rossi, Luigi Marcheselli, Alessandra Dondi, Chiara Bottelli, Alessandra Tucci, Maria Giuseppina Cabras

Am J Hematol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.
Maurizio Martelli, Luca Ceriani, Emanuele Zucca, Pier Luigi Zinzani, Andrés J M Ferreri, Maria Giuseppina Cabras

J Clin Oncol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.
Pier Luigi Zinzani, Giuseppe Rossi, Silvia Franceschetti, Barbara Botto, Alice Di Rocco, Maria Giuseppina Cabras

Clin Cancer Res· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Pier Luigi Zinzani, Vittorio Stefoni, Erica Finolezzi, Ercole Brusamolino, Maria Giuseppina Cabras

Clin Lymphoma Myeloma· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis